Canadian biotech SaNOtize said that a Phase 2 trial of its nitric oxide nasal spray (NONS) in COVID-19 patients demonstrated that the nasal spray reduced viral load by about 95% within 24 hours post dose and by more than 99% within 72 hours. In addition, clearance of the SARS-CoV-2 virus was 16 times faster for patients using NONS than for those given a placebo. Based … [Read more...] about SaNOtize to apply for emergency use authorization in UK and Canada for its NO nasal spray for COVID-19
News
Copley Scientific introduces new products for nasal spray testing
Copley Scientific, which recently made multiple updates to its range of OINDP testing equipment, has announced the launch of a new range of accessories for testing nasal sprays, including metered dose and dry powder nasal products. The new Copley products include accessories for delivered dose uniformity (DDU) testing of nasal products as well as for improved in … [Read more...] about Copley Scientific introduces new products for nasal spray testing
RDD 2021 introduces “knowledge spaces”
After having to make a last-minute switch to an online format in 2020, the organizers of the annual Respiratory Drug Delivery (RDD meeting) had more time to plan a virtual meeting for 2021, and they have introduced new features designed to create "a conference experience informed by the best features of an in-person conference augmented by a design that is only … [Read more...] about RDD 2021 introduces “knowledge spaces”
CounterAct gets US patent for its naloxone nasal spray cap
The US Patent and Trademark Office has issued US Patent No. 10,933,204, titled "Prescription bottle cap capable of administering opioid overdose reversal agent" to CounterAct for its naloxone nasal spray cap, the company said. CounterAct is developing the nasal spray cap, which is designed to snap onto the top of a prescription pill bottle, for the reversal of opioid … [Read more...] about CounterAct gets US patent for its naloxone nasal spray cap
Iconovo gets Indian patent for its ICOone DPI
DPI developer Iconovo announced that it has received its first patent in India covering the company's ICOone single dose DPI. According to the company, the ICOone platform is already covered by patents in Europe, and patents are pending in the US, China, and Japan. In December 2020, Iconovo announced that Monash University had selected ICOone for delivery of its … [Read more...] about Iconovo gets Indian patent for its ICOone DPI
Neurelis raises $114 million for commercialization of Valtoco nasal spray
Neurelis announced that it has raised $114 million in a Series D preferred stock financing to fund commercialization of Valtoco diazepam nasal spray, which was approved by the FDA for the treatment of seizure clusters or acute repetitive seizures in epilepsy patients aged 6 years and older in January 2020. Neurelis launched Valtoco in the US in March 2020. The … [Read more...] about Neurelis raises $114 million for commercialization of Valtoco nasal spray
TFF Pharmaceuticals announces agreements for feasibility studies of mRNA vaccine candidate and aviptadil
TFF Pharmaceuticals has announced agreements for feasibility studies with vaccine developer GreenLight Biosciences and with NeuroRx. TFF is performing studies to determine if dry powder formulations of GreenLight's mRNA COVID-19 vaccine candidate and NeuroRx's Zyesami aviptadil can be successfully created using TFF's thin film freezing technology. According to … [Read more...] about TFF Pharmaceuticals announces agreements for feasibility studies of mRNA vaccine candidate and aviptadil
Vectura expands its DPI manufacturing capacity
Inhalation CDMO Vectura has announced the addition of a new dry powder inhaler filling and assembly line at its facility in Chippenham, UK that will increase the company's DPI manufacturing capability to up to 1 million devices per year. The expansion is scheduled to be complete in the second quarter of 2021. The new semi-automatic line will be used for Vectura's … [Read more...] about Vectura expands its DPI manufacturing capacity
The Gates Medical Research Institute to develop dry powder lung surfactant for the treatment of RDS in premature infants
The Lundquist Institute for Biomedical Innovation (TLI, formerly LABioMed) has licensed a dry powder synthetic lung surfactant formulation to The Bill & Melinda Gates Medical Research Institute (Gates MRI), TLI said. Gates MRI plans to develop the inhalation powder for the treatment of respiratory distress syndrome (RDS) in premature infants in low- and … [Read more...] about The Gates Medical Research Institute to develop dry powder lung surfactant for the treatment of RDS in premature infants
AIM ImmunoTech initiates Phase 1 trial of intranasal Ampligen for COVID-19
AIM ImmunoTech announced that that the first subjects have been dosed in a Phase 1 safety study of an intranasal formulation of the company’s Ampligen rintatolimod, which the company is developing for the prevention and/or treatment of COVID-19. AIM announced plans for the study in January 2021. According to AIM, in vitro modeling has demonstrated that "clinically … [Read more...] about AIM ImmunoTech initiates Phase 1 trial of intranasal Ampligen for COVID-19